These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11585572)

  • 1. Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat.
    Kihara M; Mitsui Y; Shioyama M; Hasegawa T; Takahashi M; Takakura S; Minoura K; Kawamura I
    Neurosci Lett; 2001 Sep; 310(2-3):81-4. PubMed ID: 11585572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats.
    Yamamoto T; Takakura S; Kawamura I; Seki J; Goto T
    Life Sci; 2001 Feb; 68(12):1439-48. PubMed ID: 11388695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
    Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
    Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced nerve blood flow in diabetic rats: relationship to nitric oxide production and inhibition of aldose reductase.
    Tomlinson DR; Dewhurst M; Stevens EJ; Omawari N; Carrington AL; Vo PA
    Diabet Med; 1998 Jul; 15(7):579-85. PubMed ID: 9686698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats.
    Cameron NE; Cotter MA; Hohman TC
    Diabetologia; 1996 Feb; 39(2):172-82. PubMed ID: 8635669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats.
    Shimoshige Y; Minoura K; Matsuoka N; Takakura S; Mutoh S; Kamijo M
    Brain Res; 2009 Jan; 1247():182-7. PubMed ID: 18992730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447: minor contribution of nitric oxide.
    Yoshida M; Sugiyama Y; Akaike N; Ashizawa N; Aotsuka T; Ohbayashi S; Matsuura A
    Diabetes Res Clin Pract; 1998 May; 40(2):101-12. PubMed ID: 9681275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide.
    Kihara M; Mitsui MK; Mitsui Y; Okuda K; Nakasaka Y; Takahashi M; Schmelzer JD
    Muscle Nerve; 1999 Jul; 22(7):920-5. PubMed ID: 10398211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of defective peripheral nerve conduction velocity, nutritive endoneurial blood flow, and oxygenation by a novel aldose reductase inhibitor, WAY-121,509, in streptozotocin-induced diabetic rats.
    Cameron NE; Cotter MA; Dines KC; Hohman TC
    J Diabetes Complications; 1996; 10(1):43-53. PubMed ID: 8639974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes impairs sciatic nerve hyperemia induced by surgical trauma: implications for diabetic neuropathy.
    Ido Y; Chang K; LeJeune W; Tilton RG; Monafo WW; Williamson JR
    Am J Physiol; 1997 Jul; 273(1 Pt 1):E174-84. PubMed ID: 9252494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurovascular effects of L-carnitine treatment in diabetic rats.
    Cameron NE; Cotter MA
    Eur J Pharmacol; 1997 Jan; 319(2-3):239-44. PubMed ID: 9042596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT.
    Nakamura J; Koh N; Sakakibara F; Hamada Y; Wakao T; Sasaki H; Mori K; Nakashima E; Naruse K; Hotta N
    Life Sci; 1997; 60(21):1847-57. PubMed ID: 9154994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.
    Kuzumoto Y; Kusunoki S; Kato N; Kihara M; Low PA
    Diabetologia; 2006 Dec; 49(12):3085-93. PubMed ID: 17063327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological manipulation of vascular endothelium function in non-diabetic and streptozotocin-diabetic rats: effects on nerve conduction, hypoxic resistance and endoneurial capillarization.
    Cameron NE; Cotter MA; Dines KC; Maxfield EK
    Diabetologia; 1993 Jun; 36(6):516-22. PubMed ID: 8335173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
    Greene DA; Arezzo JC; Brown MB
    Neurology; 1999 Aug; 53(3):580-91. PubMed ID: 10449124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats.
    Nakamura J; Koh N; Sakakibara F; Hamada Y; Wakao T; Hara T; Mori K; Nakashima E; Naruse K; Hotta N
    Eur J Pharmacol; 1995 Dec; 294(1):207-14. PubMed ID: 8788433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
    Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of aldose reductase in alterations to neurotrophin receptors and neuronal cytoskeletal protein mRNA levels in the dorsal root ganglion of streptozotocin-induced diabetic rats.
    Shimoshige Y; Enomoto R; Aoki T; Matsuoka N; Kaneko S
    Biol Pharm Bull; 2010; 33(1):67-71. PubMed ID: 20045938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.